Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody

Cancer Communications

卷:41

Ping Wang¹  Shuo Wang¹  Yichu Yuan²  Wen Cai²  Hao Zeng³  Qiang Wei³  Haoran Zhang³  Jianming Guo⁴  Xiaoyi Hu⁴  Jin Zhang⁵  Wen Kong⁵  Wei Xue⁵  Jiwei Huang⁵  Yueming Wang⁵  Yiran Huang⁵ 

[1] Department of Urology First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang 310003 P. R. China;

[2] Department of Urology Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang 310009 P. R. China;

[3] Department of Urology West China Hospital, Sichuan University Chengdu Sichuan 610041 P. R. China;

[4] Department of Urology Zhongshan Hospital, Fudan University Shanghai 200032 P. R. China;

[5] Department of Urology, Renji Hospital School of Medicine, Shanghai Jiao Tong University Shanghai 200127 P. R. China;

关键词: ;   

DOI  :  10.1002/cac2.12206

来源: DOAJ

【 授权许可】

Unknown